Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015695 (
fatty liver
)
13,941
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lipid droplet (LD) accumulation in hepatocytes is a typical character of steatosis. Hepatitis C virus (HCV) infection, one of the risk factors related to steatosis, induced LD accumulation in cultured cells. However, the mechanisms of which HCV induce LD formation are not fully revealed. Previously we identified cytosolic phospholipase A2 gamma (
PLA2G4C
) as a host factor upregulated by HCV infection and involved in HCV replication. Here we further revealed that
PLA2G4C
plays an important role in LD biogenesis and refined the functional analysis of
PLA2G4C
in LD biogenesis and HCV assembly. LD formation upon fatty acid and HCV stimulation in
PLA2G4C
knockdown cells was impaired and could not be restored by complementation with PLA2G4A.
PLA2G4C
was tightly associated in the membrane with the domain around the amino acid residues 260-292, normally in ER but relocated into LDs upon oleate stimulation. Mutant
PLA2G4C
without enzymatic activity was not able to restore LD formation in
PLA2G4C
knockdown cells. Thus, both the membrane attachment and the enzymatic activity of
PLA2G4C
were required for its function in LD formation. The participation of
PLA2G4C
in LD formation is correlated with its involvement in HCV assembly. Finally,
PLA2G4C
overexpression itself led to LD formation in hepatic cells and enhanced LD accumulation in the liver of high-fat diet (HFD)-fed mice, suggesting its potential role in
fatty liver
disease.
...
PMID:Requirement of cytosolic phospholipase A2 gamma in lipid droplet formation. 2833 30